scPharmaceuticals Inc.
SCPH
$2.57
$0.020.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 99.31% | 164.12% | 391.70% | 195.78% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.31% | 164.12% | 391.70% | 195.78% | -- |
| Cost of Revenue | 123.63% | 206.86% | 549.72% | 195.04% | -- |
| Gross Profit | 89.34% | 147.15% | 348.13% | 196.09% | -- |
| SG&A Expenses | 31.60% | 50.83% | 44.74% | 60.12% | 126.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.44% | 51.18% | 46.16% | 61.25% | 124.72% |
| Operating Income | -7.12% | -22.29% | -4.98% | -37.23% | -60.57% |
| Income Before Tax | -36.44% | -124.54% | -20.74% | -25.85% | -49.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.44% | -124.54% | -20.74% | -25.85% | -49.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.44% | -124.54% | -20.74% | -25.85% | -49.35% |
| EBIT | -7.12% | -22.29% | -4.98% | -37.23% | -60.57% |
| EBITDA | -7.13% | -22.30% | -4.99% | -37.25% | -60.66% |
| EPS Basic | 1.01% | -86.96% | -19.85% | -22.12% | -20.34% |
| Normalized Basic EPS | 14.73% | -93.85% | -19.86% | -22.18% | -38.78% |
| EPS Diluted | 1.01% | -86.96% | -19.85% | -22.12% | -20.34% |
| Normalized Diluted EPS | 14.73% | -93.85% | -19.86% | -22.18% | -38.78% |
| Average Basic Shares Outstanding | 37.84% | 20.12% | 0.75% | 3.05% | 24.10% |
| Average Diluted Shares Outstanding | 37.84% | 20.12% | 0.75% | 3.05% | 24.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |